ライフサイエンスコーパス: tissue-type plasminogen activator

1 on time-to-thrombolytic treatment with tPA (tissue-type plasminogen activator).

2 the provisional matrix and the protease tPA (tissue-type plasminogen activator).

3 okinase-type plasminogen activator (uPA) and tissue-type plasminogen activator.

4 minogen activator (uPA) and fibrinogen-bound tissue-type plasminogen activator.

5 a dose-dependent fashion in the presence of tissue-type plasminogen activator.

6 not evaluated as early after stroke onset as tissue-type plasminogen activator.

7 or of both urinary plasminogen activator and tissue-type plasminogen activator.

8 tatic interaction between these residues and tissue-type plasminogen activator.

9 activation of cell-associated plasminogen by tissue-type plasminogen activator.

10 tamate and specific protein ligands, such as tissue-type plasminogen activator.

11 cluding activated alpha(2)-macroglobulin and tissue-type plasminogen activator.

12 roteinase (MMP)-1 and -9, and urokinase- and tissue-type plasminogen activators.

13 accompanied by up-regulation of the neuronal tissue-type plasminogen activator, a serine protease kno

14 8-bromo-cAMP, causes a dramatic increase in tissue-type plasminogen activator activity secondary to

15 n was demonstrated by complete inhibition of tissue-type plasminogen activator activity with supernat

16 with a corresponding increase in plasma PAI/tissue-type plasminogen activator activity.

17 ith bleeding complications after intravenous tissue-type plasminogen activator administration to pati

18 thway inhibitor) and hyperfibrinolysis (high tissue-type plasminogen activator) (all p < .05 vs. youn

19 ioidosis have elevated circulating levels of tissue-type plasminogen activator, an important regulato

20 ndard of care: intravenous thrombolysis with tissue-type plasminogen activator and endovascular treat

21 vator inhibitor type 1 formed a complex with tissue-type plasminogen activator and inhibited its prot

22 significant reduction in expression both of tissue-type plasminogen activator and of urokinase-type

23 activation of fibrinolysis (plasma levels of tissue-type plasminogen activator and plasmin-alpha2-ant

24 sis was not influenced by TNFR55:IgG (plasma tissue-type plasminogen activator and plasmin-alpha2-ant

25 levels) and the fibrinolytic system (plasma tissue-type plasminogen activator and plasminogen activa

26 lso providing a common binding site for both tissue-type plasminogen activator and plasminogen via it

27 t amorphous protein aggregates interact with tissue-type plasminogen activator and plasminogen, via a

28 However, in tissue-type plasminogen activator and plasminogen-defici

29 ntiation products, two well-known proteases: tissue-type plasminogen activator and urokinase, as well

30 nhibitor-1 (PAI-1), the primary inhibitor of tissue-type plasminogen activator and urokinase, is know

31 t inhibit several serine proteases including tissue-type plasminogen activator and urokinase-type pla

32 <60 minutes in >50% of patients treated with tissue-type plasminogen activator), and (5) face-to-face

33 angioplasty with a 3- to 4-hour infusion of tissue-type plasminogen activator, and 3 compared angiop

34 ligands, including matrix metalloprotease-9, tissue-type plasminogen activator, and alpha(2)-macroglo

35 ed protein, urokinase plasminogen activator, tissue-type plasminogen activator, and plasminogen activ

36 of the fibrinolytic system (plasma levels of tissue-type plasminogen activator, and plasminogen activ

37 ay containing purified thrombin, fibrinogen, tissue-type plasminogen activator, and plasminogen, clot

38 (intercellular adhesion molecule-1, ICAM-1), tissue-type plasminogen activator, and TM-inducible gluc

39 ulted in increased plasminogen activation by tissue-type plasminogen activator, and was dependent on

40 e to four weeks (p < 0.03) and a decrease in tissue-type plasminogen activator antigen from baseline

41 Tissue-type plasminogen activator antigen increased (31%

42 in cholesterol, homocysteine, triglycerides, tissue-type plasminogen-activator antigen, and C-relativ

43 ciated plasmin-induced fibrinolysis and/or a tissue-type plasminogen activator-associated decrease in

44 These effects are related to tissue-type plasminogen activator-associated plasmin-ind

45 plasminogen activator at pH 6.2-8.0 and for tissue-type plasminogen activator at pH 6.2.

46 The LRP1 agonists, alpha2-macroglobulin and tissue-type plasminogen activator, attenuated expression

47 demonstrated that hepsin did not cleave pro-tissue-type plasminogen activator but efficiently conver

48 Canada are limited at present to intravenous tissue-type plasminogen activator, but bleeding complica

49 Intravenous tissue-type plasminogen activator can be beneficial to s

50 uding plasminogen activators (urokinase- and tissue-type plasminogen activators), coagulation enzymes

51 Wild-type and tissue-type plasminogen activator-deficient C57BL/6 mice

52 ng infection with Burkholderia pseudomallei, tissue-type plasminogen activator-deficient mice were pr

53 with an early increase in cytokine levels in tissue-type plasminogen activator-deficient mice.

54 rs formed with decorin underwent accelerated tissue-type plasminogen activator-dependent fibrinolysis

55 conventional approaches such as recombinant tissue-type plasminogen activator, direct thrombin inhib

56 Accelerated tPA (tissue-type plasminogen activator) dosing regimens for u

57 ce, we bred urokinase plasminogen activator, tissue-type plasminogen activator double knockouts.

58 s study, we aimed to investigate the role of tissue-type plasminogen activator during melioidosis.

59 Enzymatically inactive tissue-type plasminogen activator (EI-tPA) does not acti

60 nditioning hiNPC with enzymatically-inactive tissue-type plasminogen activator (EI-tPA), prior to gra

61 ide (LPS), including: enzymatically-inactive tissue-type plasminogen activator (EI-tPA); activated al

62 ligands, including alpha2-macroglobulin and tissue-type plasminogen activator, failed to cause LRP1

63 n (81%) were treated with intracoronary tPA (tissue-type plasminogen activator) followed by systemic

64 STO (Global Utilization of Streptokinase and Tissue-Type Plasminogen Activator for Occluded Coronary

65 low-dose (25 mg), slow infusion (6 hours) of tissue-type plasminogen activator for the treatment of p

66 lobal Utilization of Streptokinase and t-PA [tissue-type plasminogen activator] for Occluded Coronary

67 Changes in tissue-type plasminogen activator gene expression do not

68 sed by Burkholderia pseudomallei, endogenous tissue-type plasminogen activator has harmful effects wi

69 Tissue-type plasminogen activator, however, is not neces

70 nd more eligible patients to be treated with tissue-type plasminogen activator if onset is </=2 hours

71 dosis was associated with elevated levels of tissue-type plasminogen activator in lungs of infected w

72 tor-1 is the main physiological regulator of tissue-type plasminogen activator in normal plasma.

73 Some studies have shown elevated tissue-type plasminogen activator in pemphigus lesions.

74 1, 2010 and March 31, 2015 and who received tissue-type plasminogen activator in the emergency depar

75 10 patients with IS treated with intravenous tissue-type plasminogen activator in the Get With The Gu

76 ling proteins showed a higher abundance (eg, tissue-type plasminogen activator) in early compared wit

77 n plasma of pregnant women inhibits FXIa and tissue-type plasminogen activator-induced clot fibrinoly

78 Mean alteplase (r-tPA [recombinant tissue-type plasminogen activator]) infusion duration wa

79 formation but did not affect plasminogen and tissue-type plasminogen activator interactions with Fgal

80 ng patients with IS treated with intravenous tissue-type plasminogen activator is associated with hig

81 ents with acute ischemic stroke treated with tissue-type plasminogen activator is associated with imp

82 rt-PA (recombinant tissue-type plasminogen activator) is an effective treat

83 Intravenous rt-PA (recombinant tissue-type plasminogen activator) is effective in impro

84 s known regarding outcomes after intravenous tissue-type plasminogen activator (IV tPA) therapy for a

85 ecommend against the use of intravenous tPA (tissue-type plasminogen activator; IV tPA) in acute isch

86 ulin G caused blisters to the same degree in tissue-type plasminogen activator knockout and control m

87 By interacting with active tissue-type plasminogen activator, LDL receptor-related

88 acute ischemic stroke with intravenous tPA (tissue-type plasminogen activator) may increase the risk

89 man plasminogen and facilitated the latter's tissue-type plasminogen activator-mediated activation to

90 -inducing activity of IGFBP3 is inhibited by tissue-type plasminogen activator-mediated proteolysis,

91 nase-type plasminogen activator mRNA but not tissue-type plasminogen activator mRNA correlated with f

92 several partially purified preparations of a tissue-type plasminogen activator mutant (TNK-tPA).

93 n agreement, the influence of plasminogen or tissue-type plasminogen activator on binding of apo(a) t

94 oplasty with "accelerated" administration of tissue-type plasminogen activator over 90 minutes.

95 ts function as an inhibitor of urokinase and tissue-type plasminogen activator (PA), PA inhibitor-1 (

96 ERK phosphorylation was not induced by tissue-type plasminogen activator-PAI-1 complex or by uP

97 ine proteases urinary plasminogen activator, tissue-type plasminogen activator, plasmin and thrombin

98 ytic system (plasminogen activator activity, tissue-type plasminogen activator, plasminogen activator

99 on of fibrinolysis (plasma concentrations of tissue-type plasminogen activator, plasminogen activator

100 of the fibrinolytic system (plasma levels of tissue-type plasminogen activator, plasminogen activator

101 The fibrinolytic variables, tissue-type plasminogen activator, plasminogen activator

102 inogen, factor XIII), fibrinolysis (D-dimer, tissue-type plasminogen activator, plasminogen activator

103 action of apo(a) with the ternary complex of tissue-type plasminogen activator, plasminogen and fibri

104 ronectin, vitronectin, laminin, single-chain tissue-type plasminogen activator, plasminogen, or any p

105 The predictive value of plasma levels of tissue-type plasminogen activator, platelet activator in

106 ms (MT1B/MT1A/MT-1F; from 2.9- to 3.2-fold), tissue-type plasminogen activator precursor (PLAT; 2.8-f

107 the isolated recombinant kringle 2 domain of tissue-type plasminogen activator (r-K2tPA), an amino ac

108 plasminogen activator (t-PA) and recombinant tissue-type plasminogen activator (r-PA).

109 National guidelines endorse recombinant tissue-type plasminogen activator (r-tPA) in eligible pa

110 given to IL-10 (-/-) mice normalized the PAI/tissue-type plasminogen activator ratio, reduced pulmona

111 duced thrombus formation, and an increase in tissue-type plasminogen activator release.

112 Intravenous thrombolysis with tissue-type plasminogen activator remains the mainstay o

113 Faster delivery of tPA (tissue-type plasminogen activator) results in better hea

114 sttreatment of stroke with recombinant human tissue-type plasminogen activator (rht-PA) constrains th

115 e randomized to a 50-mg bolus of recombinant tissue-type plasminogen activator (rt-PA) (alpha half-li

116 Recombinant tissue-type plasminogen activator (rt-PA) improves outco

117 amma (rIFN-gamma, Actimmune) and recombinant tissue-type plasminogen activator (rt-PA, Activase) to m

118 705 patients received alteplase (recombinant tissue-type plasminogen activator [rt-PA]).

119 will maximally accelerate thrombolysis by r-tissue-type plasminogen activator (rTPA) and reduce resi

120 were exposed to 10 to 1000 ng/mL recombinant tissue-type plasminogen activator (RTPA), urokinase-type

121 extended release of W253R/R275S recombinant tissue-type plasminogen activator (rtPA).

122 Studies on enzymatic activity of tissue-type plasminogen activator show that polynitrosyl

123 An aerosolized fibrinolytic agent, tissue-type plasminogen activator, significantly diminis

124 the chymotrypsin family of serine proteases, tissue type plasminogen activator (t-PA) is not synthesi

125 s 120 times more efficiently by u-PA than by tissue type plasminogen activator (t-PA), an intimately

126 study compared the activities of recombinant tissue-type plasminogen activator (t-PA) and a plasminog

127 s is regulated in part by the interaction of tissue-type plasminogen activator (t-PA) and plasminogen

128 identified the currently available doses of tissue-type plasminogen activator (t-PA) and recombinant

129 for two intimately related serine proteases, tissue-type plasminogen activator (t-PA) and urokinase-t

130 Tissue-type plasminogen activator (t-PA) can modulate pe

131 Tissue-type plasminogen activator (t-PA) has evolved to

132 ptide (TAP), after thrombolytic therapy with tissue-type plasminogen activator (t-PA) in a canine mod

133 Human colon fibroblasts (HCF) produce tissue-type plasminogen activator (t-PA) in culture, but

134 The serine protease tissue-type plasminogen activator (t-PA) initiates the f

135 Tissue-type plasminogen activator (t-PA) is a serine pro

136 The gene encoding tissue-type plasminogen activator (t-PA) is an immediate

137 the vascular endothelium locally to release tissue-type plasminogen activator (t-PA) is critical for

138 the chymotrypsin family of serine proteases, tissue-type plasminogen activator (t-PA) is not synthesi

139 n this study, we demonstrate that VDAC binds tissue-type plasminogen activator (t-PA) on human neurob

140 from all 358 patients with AMI randomized to tissue-type plasminogen activator (t-PA) or primary PTCA

141 ut not noncovalent Michaelis complexes, with tissue-type plasminogen activator (t-PA) or urokinase (u

142 t are efficiently and selectively cleaved by tissue-type plasminogen activator (t-PA) or urokinase-ty

143 t to define the local regulation of vascular tissue-type plasminogen activator (t-PA) release.

144 y of vascular endothelium to locally release tissue-type plasminogen activator (t-PA) represents an i

145 ting enzyme (ACE) inhibition potentiates the tissue-type plasminogen activator (t-PA) response to exo

146 ve 30-day mortality benefit with accelerated tissue-type plasminogen activator (t-PA) versus streptok

147 Tissue-type plasminogen activator (t-PA), for example, p

148 Plasma levels of tissue-type plasminogen activator (t-PA), plasminogen ac

149 1 patients randomized to receive accelerated tissue-type plasminogen activator (t-PA), streptokinase

150 ract differently with streptokinase (SK) and tissue-type plasminogen activator (t-PA), which could re

151 is has been dominated by the experience with tissue-type plasminogen activator (t-PA), which proved l

152 dy, we demonstrate that GRP78 also binds the tissue-type plasminogen activator (t-PA), which results

153 A 15% reduction in mortality for the tissue-type plasminogen activator (t-PA)-treated group w

154 o receive primary angioplasty or accelerated tissue-type plasminogen activator (t-PA).

155 imultaneous decrease in the concentration of tissue-type plasminogen activator (t-PA)/PAI-1 complexes

156 After >/=60 minutes of occlusion, tissue-type plasminogen activator (t-PA; 1.42 mg/kg) was

157 and inflammatory marker proteins (including tissue-type plasminogen activator [t-PA], plasminogen ac

158 l evidence that maspin specifically inhibits tissue-type plasminogen activator that is associated wit

159 solve thrombi acutely and r-tPA (recombinant tissue-type plasminogen activator) therapy may be requir

160 333 patients (24%) who received recombinant tissue-type plasminogen activator, there was also no ben

161 Clots were formed in the presence of tissue-type plasminogen activator, thrombin, phosphatidy

162 In contrast, uPA(-/-) and tissue-type plasminogen activator tPA(-/-) mice, but not

163 Tissue type plasminogen activator (tPA) is a key enzyme

164 urified protein is an efficient inhibitor of tissue type plasminogen activator (tPA), having an appar

165 e FDA approved treatment for acute stroke is tissue type plasminogen activator (tPA).

166 e demonstrate that an increase in endogenous tissue-type plasminogen activator (tPA) activity in the

167 ks urokinase plasminogen activator (uPA) and tissue-type plasminogen activator (tPA) activity.

168 axons at synaptic regions where it controls tissue-type plasminogen activator (tPA) activity.

169 l analysis of fibrinolysis after recombinant tissue-type plasminogen activator (tPA) administration r

170 ing further reduction in treatment times for tissue-type plasminogen activator (tPA) administration.

171 Tissue-type plasminogen activator (tPA) also bound to VS

172 Although both tissue-type plasminogen activator (tPA) and matrix metal

173 We measured plasma antigen levels of tissue-type plasminogen activator (tPA) and plasminogen

174 t defensin inhibits fibrinolysis mediated by tissue-type plasminogen activator (tPA) and plasminogen.

175 trinsic tryptophan fluorescence of two-chain tissue-type plasminogen activator (tPA) and the proteina

176 The serine proteinase tissue-type plasminogen activator (tPA) and the serine p

177 ptide-blocked PAI-1 was a substrate for both tissue-type plasminogen activator (tPA) and trypsin and

178 Increased expression of tissue-type plasminogen activator (tPA) and urokinase-ty

179 tor-1 (PAI-1) to serine proteinases, such as tissue-type plasminogen activator (tPA) and urokinase-ty

180 teolysis, we explored the regulatory role of tissue-type plasminogen activator (tPA) and urokinase-ty

181 controls; in contrast, transcripts for both tissue-type plasminogen activator (tPA) and urokinase-ty

182 ivated into plasmin by two serine proteases: tissue-type plasminogen activator (tPA) and urokinase-ty

183 activator inhibitor 1 (PAI-1) that preserved tissue-type plasminogen activator (tPA) and urokinase-ty

184 opulmonary bypass (CPB) on PAI-1 antigen and tissue-type plasminogen activator (tPA) antigen and acti

185 ee measures of plasma fibrinolytic activity: tissue-type plasminogen activator (TPA) antigen, plasmin

186 (Fn) enhances plasminogen (Pg) activation by tissue-type plasminogen activator (tPA) by serving as a

187 Tissue-type plasminogen activator (tPA) catalyzes the ra

188 A fibrinolytic agent consisting of a tissue-type plasminogen activator (tPA) coupled to the s

189 Regulation of tissue-type plasminogen activator (tPA) depends on fibri

190 e hypothesis, namely, that marked release of tissue-type plasminogen activator (tPA) followed by dela

191 Hypoxia induces the release of tissue-type plasminogen activator (tPA) from cerebral co

192 cations of the thrombomodulin (TM) gene, the tissue-type plasminogen activator (tPA) gene, and the ur

193 w bolus fibrinolytics derived from the human tissue-type plasminogen activator (tPA) have emerged as

194 After obstructive injury, mice lacking tissue-type plasminogen activator (tPA) have fewer myofi

195 ates have been synthesized and evaluated for tissue-type plasminogen activator (tPA) hydrolysis in an

196 al trials suggest the benefit of intravenous tissue-type plasminogen activator (tPA) in acute ischemi

197 The benefits of intravenous tissue-type plasminogen activator (tPA) in acute ischemi

198 After stroke, the thrombolytic effect of tissue-type plasminogen activator (tPA) in the intravasc

199 The clinical use of tissue-type plasminogen activator (tPA) in the treatment

200 Assembled A beta is a potent stimulator of tissue-type plasminogen activator (tPA) in vitro.

201 functioning as an activator of fibrinolysis, tissue-type plasminogen activator (tPA) interacts with n

202 Tissue-type plasminogen activator (tPA) is a highly spec

203 Tissue-type plasminogen activator (tPA) is a major media

204 Here we show that tissue-type plasminogen activator (tPA) is a potent mito

205 Tissue-type plasminogen activator (tPA) is a serine prot

206 Tissue-type plasminogen activator (tPA) is a serine prot

207 e best-known function of the serine protease tissue-type plasminogen activator (tPA) is as a thrombol

208 Tissue-type plasminogen activator (tPA) is known to prom

209 Tissue-type plasminogen activator (tPA) is one of the ma

210 Tissue-type plasminogen activator (tPA) is the major int

211 1 (PAI-1), a rapid inhibitor of both uPA and tissue-type plasminogen activator (tPA) is the major phy

212 Tissue-type plasminogen activator (tPA) is the only ther

213 Thrombolysis with tissue-type plasminogen activator (tPA) is used for the

214 estatic liver disease in mice suggested that tissue-type plasminogen activator (tPA) or urokinase pla

215 Tissue-type plasminogen activator (tPA) promoted TGF-bet

216 Tissue-type plasminogen activator (tPA) regulates physio

217 Immunodepletion of tissue-type plasminogen activator (tPA) resulted in part

218 ranular colocalization of GH with endogenous tissue-type plasminogen activator (tPA) was also demonst

219 strated benefit to expanding the intravenous tissue-type plasminogen activator (tPA) window from 3 to

220 domized, blinded, dose-ranging comparison of tissue-type plasminogen activator (TPA) with a direct-ac

221 Tissue-type plasminogen activator (tPA), a protease up-r

222 Tissue-type plasminogen activator (tPA), a serine protea

223 on of some early markers of differentiation, tissue-type plasminogen activator (tPA), AFP and keratin

224 urokinase-type plasminogen activator (uPA), tissue-type plasminogen activator (tPA), and plasma kall

225 activator (uPA), urokinase receptor (uPAR), tissue-type plasminogen activator (tPA), and plasminogen

226 L insertion for reactions with beta-trypsin, tissue-type plasminogen activator (tPA), and urokinase.

227 roserpin, a recently identified inhibitor of tissue-type plasminogen activator (tPA), is primarily lo

228 d thrombolysis, with either streptokinase or tissue-type plasminogen activator (tPA), on argatroban's

229 ll-free system, plasminogen activators [uPA, tissue-type plasminogen activator (tPA), or streptokinas

230 PAI-1, the primary physiologic regulator of tissue-type plasminogen activator (tPA), prolonged the t

231 n the luminal surface expressed the mRNA for tissue-type plasminogen activator (TPA), urokinase type

232 a showed a temporally enhanced expression of tissue-type plasminogen activator (tPA), urokinase-type

233 Whereas tissue-type plasminogen activator (tPA), which converts

234 oxypeptidase activity in human plasma delays tissue-type plasminogen activator (TPA)-induced clot lys

235 family that binds several ligands, including tissue-type plasminogen activator (tPA).

236 logical effect of ICAM-directed targeting of tissue-type plasminogen activator (tPA).

237 tor (uPA), and can also produce both uPA and tissue-type plasminogen activator (tPA).

238 mpared to those of a known HGF/SF activator, tissue-type plasminogen activator (tPA).

239 namic transfection of a plasmid encoding for tissue-type plasminogen activator (tPA).

240 e expression of a known activator of HGF/SF, tissue-type plasminogen activator (tPA).

241 dard thrombolytic treatment with recombinant tissue-type plasminogen activator (tPA).

242 ide insight into the source of intravascular tissue-type plasminogen activator (tPA).

243 Using mice deficient in tissue-type plasminogen activator (tPA-/-) and urokinase

244 Thrombolytics (eg, tissue-type plasminogen activator [tPA]) cannot be used

245 hy confirmed clot dissolution in recombinant tissue-type plasminogen activator-treated animals, but e

246 here were 15 191 of 44 410 (34%) intravenous tissue-type plasminogen activator-treated IS patients wi

247 of the thrombus was detected in recombinant tissue-type plasminogen activator-treated rats but not i

248 ve thrombosis model) followed by recombinant tissue-type plasminogen activator treatment (10 mg/kg, I

249 th recovery scores after accounting for tPA (tissue-type plasminogen activator) treatment.

250 red with prothrombin-deficient plasma delays tissue-type plasminogen activator-triggered lysis; this

251 Additionally, tissue-type plasminogen activator triggers activation of

252 not observed with proteases like trypsin and tissue-type plasminogen activator, unless the RGD sequen

253 mice individually deficient for plasminogen, tissue-type plasminogen activator, urokinase-type plasmi

254 tion for Acute Ischemic Stroke network: tPA (tissue-type plasminogen activator) use, complications re

255 The mean dose of tissue-type plasminogen activator used was 48.7+/-29.5 m

256 Between 2004 and 2012, tissue-type plasminogen activator was administered to 24

257 Recently, thrombolytic therapy with tissue-type plasminogen activator was approved for selec

258 Plasminogen activation by tissue-type plasminogen activator was greatly accelerate

259 The total dose of r-tPA (recombinant tissue-type plasminogen activator) was 14 mgs in bilater

260 Median levels of tissue-type plasminogen activator were also significantl

261 modulates the interaction of plasminogen and tissue-type plasminogen activator with cultured human en

262 in(ogen) alphaC-domains bind plasminogen and tissue-type plasminogen activator with high affinity in

263 TEMI enrolled in the Enoxaparin Tenecteplase-Tissue-Type Plasminogen Activator With or Without Glycop

264 Low-dose, slow infusion of tissue-type plasminogen activator with repeated doses as

265 s heparin; (3) streptokinase plus alteplase (tissue-type plasminogen activator) with intravenous hepa

266 ement and supplement intravenous recombinant tissue-type plasminogen activator within the first 3 hou

267 Analogous reaction of tissue-type plasminogen activator yields comparable NO p